RODOLFO IPPOLITI
Has grant
FULL PROFESSOR OF MOLECULAR BIOLOGY
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Rodolfo Ippoliti is a Full Professor of Molecular Biology at Università degli Studi dell'Aquila, Italy. His research focuses on molecular mechanisms in cancer therapy, including antibody-drug conjugates and bio-tailored sensing at the nanoscale. Recent articles highlight his work on therapeutic targets in glioblastoma and the implications of environmental toxins on developmental biology.
Recent Grants
Grant: Close
Produzione di proteine ricombinanti in Pichia pastoris
Open Date: 2019-06-01
Close Date: 2020-06-01
Grant: Close
Generazione di un innovativo anticorpo-farmaco non internalizzante
Open Date: 2018-10-01
Close Date: 2020-02-01
Grant: Close
PRODUZIONE E CARATTERIZZAZIONE DI UN KIT DIAGNOSTICO PER IL CANCRO DEL CAVO ORALE
Open Date: 2018-03-01
Close Date: 2018-12-01
Grant: Close
Caratterizzazione di un coniugato tra l'anticorpo 1959 ed il farmaco DM1
Open Date: 2016-06-01
Close Date: 2016-12-01
Grant: Close
TEST DI FUNZIONAMENTO IN VITRO ED IN VIVO DEL SISTEMA DI RILASCIO IN SITU DI UN CONIUGATO TRA L'ANTICORPO MONOCLONALE 1959 ED IL FARMACO DM1.
Open Date: 2015-06-01
Close Date: 2015-12-01
Articles (19)
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Affibodies and designed ankyrin repeat proteins (DARPins) are synthetic proteins originally derived from the Staphylococcus aureus virulence factor protein A and the human ankyrin repeat proteins, respectively. The use of these molecules in healthcare has been recently proposed as they are endowed with biochemical and biophysical features heavily demanded to target and fight diseases, as they have a strong binding affinity, solubility, small size, multiple functionalization sites, biocompatibility, and are easy to produce; furthermore, impressive chemical and thermal stability can be achieved. especially when using affibodies. In this sense, several examples reporting on affibodies and DARPins conjugated to nanomaterials have been published, demonstrating their suitability and feasibility in nanomedicine for cancer therapy. This minireview provides a survey of the most recent studies describing affibody- and DARPin-conjugated zero-dimensional nanomaterials, including inorganic, organic, and biological nanoparticles, nanorods, quantum dots, liposomes, and protein- and DNA-based assemblies for targeted cancer therapy in vitro and in vivo.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (15)
Elisabetta Benedetti
University of L'Aquila
Rita RONCONE
Professore Ordinario di Psichiatria
University of L'Aquila
Miryam Perrucci
University of Teramo
Radosveta Gencheva
Karolinska Institutet
Francesco ANGELUCCI
Full Professor of Biochemistry
University of L'Aquila
Mariano Catanesi
University of L'Aquila
Matteo Ardini
-
Nicoletta ZOPPI
Professor
University of Brescia
Francesco Giansanti
Associate Professor
University of L'Aquila
Ruggero De Paulis
Saint Camillus International University of Health Sciences
Marcello Locatelli
Associate professor in ANALYTICAL CHEMISTRY
University “G. d’Annunzio” of Chieti-Pescara
Francesco Brancati
Professor
University of L'Aquila
Gianluca Sala
Associate Professor
University of Chieti-Pescara
Samantha Delaney
Faculty of Health and Medical Sciences, University of Copenhagen
Outi Keinänen
The University of Alabama
Make your next move.
Prepare your application
Review drafts before you send them.